These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8103021)

  • 1. Quality of healing in peptic ulcer disease--are H2 receptor antagonists all we need?
    Korman MG
    Gastroenterol Jpn; 1993 May; 28 Suppl 5():168-71. PubMed ID: 8103021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of initial therapy on outcome of peptic ulcer.
    Korman MG
    Scand J Gastroenterol Suppl; 1995; 208():21-3. PubMed ID: 7777799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
    Liu CC; Lee CL; Chan CC; Tu TC; Liao CC; Wu CH; Chen TK
    Arch Intern Med; 2003 Sep; 163(17):2020-4. PubMed ID: 14504114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease.
    Penston JG
    Aliment Pharmacol Ther; 1996 Aug; 10(4):469-86. PubMed ID: 8853751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with H2-receptor antagonist until assessment of Helicobacter pylori eradication can reduce recurrence of peptic ulcer after successful eradication of the organism: prospective randomized controlled trial.
    Murakami K; Sato R; Okimoto T; Watanabe K; Nasu M; Kodama M; Fujioka T
    J Gastroenterol Hepatol; 2006 Jun; 21(6):1048-53. PubMed ID: 16724993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical issues in the pathophysiology and management of peptic ulcer disease.
    Hunt RH; Malfertheiner P; Yeomans ND; Hawkey CJ; Howden CW
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):685-99. PubMed ID: 8590166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helicobacter pylori eradication: therapy other than with bismuth or proton-pump inhibitors.
    Korman MG
    Scand J Gastroenterol Suppl; 1996; 220():41-3. PubMed ID: 8898434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease.
    Tomita T; Fukuda Y; Tamura K; Tanaka J; Hida N; Kosaka T; Hori K; Sakagami T; Satomi M; Shimoyama T
    Aliment Pharmacol Ther; 2002 Apr; 16 Suppl 2():204-9. PubMed ID: 11966543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug therapy of peptic ulcer disease.
    Ching CK; Lam SK
    Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptic ulcer recurrence after Helicobacter pylori eradication: a 5-year follow-up study.
    Fujioka T; Uribe RU; Kubota T; Murakami K; Kawasaki H; Nasu M
    Eur J Gastroenterol Hepatol; 1995 Aug; 7 Suppl 1():S35-8. PubMed ID: 8574733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication.
    Tan AC; Hartog GD; Mulder CJ
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1519-22. PubMed ID: 10571610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of Helicobacter pylori eradication therapy on the healing process of peptic ulcers].
    Imaizumi H; Koizumi W; Nakai H; Tanabe S; Ohida M; Saigenji K
    Nihon Rinsho; 1999 Jan; 57(1):167-72. PubMed ID: 10036957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapy for peptic ulcer--who needs it?
    McCarthy DM
    Gastroenterol Jpn; 1993 May; 28 Suppl 5():172-7. PubMed ID: 8103022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of the eradication of Helicobacter pylori on peptic ulcer healing].
    Harase I; Okuda J; Ida K
    Nihon Rinsho; 1999 Jan; 57(1):162-6. PubMed ID: 10036956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptic ulcer disease: an update.
    Berardi RR; Dunn-Kucharski VA
    Am Pharm; 1993 Jun; NS33(6):26-34. PubMed ID: 8100116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term management of peptic ulcer disease: current role of H2-antagonists.
    Brooks WS
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():47-52. PubMed ID: 1349553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents.
    Sanders SW
    Clin Ther; 1996; 18(1):2-34; discussion 1. PubMed ID: 8851451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptic ulcer--a new look.
    Kang JY
    Ann Acad Med Singap; 1995 Mar; 24(2):218-23. PubMed ID: 7653963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.
    Soll AH
    JAMA; 1996 Feb; 275(8):622-9. PubMed ID: 8594244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.